Abstract:Aberrant signal transduction regulating cell growth and proliferation is a hallmark of many cancers. Activation of mTOR signaling is common and is an attractive therapeutic target with mechanistically different mTOR inhibitors in clinical use. One consequence of exposure to the mTOR inhibitor rapamycin is an alteration of gene expression through a global increase in alternative exon inclusion (Cheng et al. 2022, doi.org/10.3390/ijms232012416). To examine the mechanisms underlying this effect, we utilized the TempO-Seq targeted sequencing platform to profile both the whole transcriptome and a selection of alternatively spliced RNA targets in the rapamycin sensitive and resistant breast cancer cell lines MCF-7 and MDA MB 231 following exposure to 13 mTOR inhibitors, some closely related and some from distinct chemical classes. Recent publications have demonstrated that high quality dose response data can be obtained using this sequencing platform (Harrill et al. 2021, doi: 10.1093/toxsci/kfab009; Ramaiahgari et al. 2019, doi: 10.1093/toxsci/kfz065) and TempO-Seq has been widely adopted in toxicology for deriving compound-specific expression signatures to identify mechanisms of action and long-term toxicity. Treated cells were also profiled using TempO-LINC, a novel high-throughput single-cell assay based on the same platform. We observed that certain mTOR inhibitors induced both common and cell-specific differential expression as well as widespread alternative exon inclusion, as expected. Intriguingly, transcripts with the most significant changes in splicing upon treatment were those encoding members of the SR family of splicing factors, often overexpressed or amplified in breast cancers (Park, et al. 2019, doi: 10.1016/j.celrep.2019.10.110). This is significant because SR protein expression is autoregulated by alternative inclusion of an exon containing a premature stop codon in a feedback loop leading to nonsense-mediated decay (NMD) and lowered protein levels. Indeed, NMD is known to be inhibited by rapamycin (Martinez-Nunez, et al. 2017, doi: 10.1093/nar/gkw1109), which would lead to the observed accumulation of these transcripts. Thus, monitoring a targeted selection of alternative splicing events and regulators revealed mTOR regulation of mRNA isoform abundance consistent with regulation of the NMD RNA turnover process and with overexpression of SR proteins in breast cancers. Importantly, targeted bulk and single-cell TempO-Seq assays enable efficient sequencing and simplified data analysis without the expense and bioinformatic burden of RNAseq, making them particularly well-suited for drug discovery. These results support the use of this approach for further characterization of cell-specific effects of mTOR inhibitors and their mechanisms of action. Citation Format: Gaelle Rondeau, Megan Opichka, Kevin White, Joanne M. Yeakley, Dennis J. Eastburn, Bruce Seligmann. Mechanistic insight into mTOR signaling identifies RNA splicing machinery as a potential therapeutic target for cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1670.

Coupling shRNA screens with single-cell RNA-seq identifies a dual role for mTOR in reprogramming-induced senescence

Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells.

mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: A roadmap from energy metabolism to stem cell renewal and aging

mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype

Autophagy and mTORC1 regulate the stochastic phase of somatic cell reprogramming

An Elaborate Regulation of Mammalian Target of Rapamycin Activity is Required for Somatic Cell Reprogramming Induced by Defined Transcription Factors

The mTORC1-autophagy pathway is a target for senescent cell elimination

A large-scale CRISPR screen and identification of essential genes in cellular senescence bypass.

Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing

Mettl14-driven senescence-associated secretory phenotype facilitates somatic cell reprogramming

Unveiling E2F4, TEAD1 and AP-1 as regulatory transcription factors of the replicative senescence program by multi-omics analysis

A Serial Shrna Screen for Roadblocks to Reprogramming Identifies the Protein Modifier SUMO2

RNAi Reveals Phase-Specific Global Regulators of Human Somatic Cell Reprogramming

Functional CRISPR screen identifies AP1-associated enhancer regulating FOXF1 to modulate oncogene-induced senescence

mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership

Abstract 1670: Mechanistic insight into mTOR signaling identifies RNA splicing machinery as a potential therapeutic target for cancer

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation

Mtorc1‐pgc1 Axis Regulates Mitochondrial Remodeling During Reprogramming

AP-1 imprints a reversible transcriptional programme of senescent cells

Multiplexed single-cell imaging reveals diverging subpopulations with distinct senescence phenotypes during long-term senescence induction.

p16 High senescence restricts cellular plasticity during somatic cell reprogramming